Summary
Three permanent clones were derived from a single astrocytoma cell line and were characterized for in vitro cell kinetics, chromosomal properties and for their responses to the anticancer drugs: 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU); 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU); 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea) (PCNU); and 1,2:5,6-dianhydrogalactitol (GAL); all of which have been shown to cross the blood brain barrier. The clones showed different population doubling times, saturation densities, plating efficiencies, chromosome counts, ploidy, cell cycle phase distributions and DNA indices. The only positive correlation among these parameters was between the population doubling times and the modal chromosome numbers; the lower the chromosome number, the shorter the doubling time. No correlation was observable between any of the cellular properties and responses to the four drugs. The clones showed a differential sensitivity to the nitrosoureas, seen maximally as a 600-fold difference in survival between two of the clones treated with the same dose of BCNU. In contrast, the clones exhibited almost identical and uniform sensitivities to galactitol, suggesting that this agent exerted its cytotoxic effects by similar mechanisms in each of the clones. By comparison BCNU (at the tested doses and duration of drug exposure used in this study) was found to be the most effective of the agents tested.
Similar content being viewed by others
References
Edwards MS, Levin VA, Wilson CB: Brain tumor chemotherapy: an evaluation of agents in current use for Phase I and II trials. Cancer Treat Rep 64:1179–1205, 1980
Tsuruo T, Fidler IJ: Differences in drug sensitivity among tumor cells from parent tumors, selected variants, and spontaneous metastases. Cancer Res 41:3058–3064, 1981
Barranco SC, Haenelt BR, Gee EL: Differential sensitivities of five rat hepatoma cell lines to anticancer drugs. Cancer Res 38:656–660, 1978
Romsdahl MM, Hsu TC: Establishment and biologic properties of human malignant melanoma cell lines grown in vitro. Surg Forum 18:78–79, 1967
Zante J, Schumann J, Barlogie B, Göhde W, Büchner T: New preparation and staining procedures for specific and rapid analysis of DNA distribution. In: Göhde W, Schumann J, Büchner T (eds): Pulse-Cytophotometry. European Press, Ghent, Belgium, 1976, pp. 97–106
Guseman LF, Bryant J: Mathematic modeling and analysis of flow microfluorometry DNA distributions. In: Lutz D (ed): Pulse Cytophotometry. European Press, Ghent, Belgium, 1978, pp. 79–92
Barlogie B, Göhde W, Johnston DA, Smallwood L, Schumann J, Drewinko B, Freireich EJ: Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res 38:3333–3339, 1978
Levin VA, Wilson CB: Chemotherapy: the agents in current use. Seminars in Oncology 2:63–72, 1975
Walker MD: Chemotherapy adjuvant to surgery and radiation therapy. Semin Oncol 2:69–72, 1975
Hoshino T, Nomura K, Wilson CB, Knebel KD, Gray JW: The distribution of nuclear DNA from human brain-tumor cells. J Neurosurg 49:13–21, 1978
Lehmann J, Krug H: Flow-through fluorocytophotometry of different brain tumors. Acta Neuropathol (Berl) 49:123–132, 1980
Borchers H, Beck H-P: Flow cytometric malignancy grading of brain tumors. Basic Appl Histochem 24:364, 1980
Mørk SJ, Laerum OD: Modal DNA content of human intracranial neoplasms studied by flow cytometry. J Neurosurg 53:198–204, 1980
Mark J: Chromosome patterns in benign and malignant tumors in the human nervous system. In German J (ed) Chromosomes and Cancer, Wiley, New York, 1974, pp. 481–495
Mark J, Westermark B, Ponten J, Hugosson R: Banding patterns in human glioma cell lines. Hereditas 87:243–260, 1977
Barranco SC, Novak JK, Humphrey RM: Studies on recovery from chemically induced damage in mammalian cells. Cancer Res 35:1194–1204, 1975
Bertrant M, Deen DF, Hoshino T, Knebel K: Recovery from potentially lethal damage induced by spirohydantoin mustard on 9L cells in vitro. Cancer Treat Rep 64:889–895, 1980
Hahn GM, Ray GR, Gordon LF, Kallman RF: Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2 and 24 hour exposure. J Natl Cancer Inst 50:529–533, 1973
Barranco SC, Drewinko B, Humphrey RM: Differential response by human melanoma cells to 1,3-Bis(2-chloroethyl)-1-nitrosourea and bleomycin. Mutat Res 19:277–280, 1973
Barranco SC, Humphrey RM: The effects of β-2′ Deoxythioguanosine on survival and progression in mammalian cells. Cancer Res 31:583–586, 1971
Biedler JL, Riehm H, Peterson RHF, Spengler BA: Membrane-mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells. J Natl Cancer Inst 55:671–680, 1975
Danø K: Development of resistance to daunomycin in Ehrlich ascites tumor. Cancer Chemother Rep 55:133–141, 1971
Harris M: Phenotypic expression of drug resistance in hybrid cells. J Natl Cancer Inst 50:423–429, 1973
Barranco SC, Ho DHW, Drewinko B, Romsdahl MM, Humphrey RM: Differential sensitivities of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res 32:2733–2736, 1972
Schimke RT, Alt FW, Kellems RE, Kaufman RJ, Bertino JR: Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells. Cold Spring Harbor Symposium Quant Biol 42:649–657, 1978
LePage GA, Junga IG, Bowman B: Biochemical and carcinostatic effects of 2′-deoxythioguanosine. Cancer Res 24:835–840, 1964
Yung W-KA, Shapiro JR, Shapiro WR: Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42:992–998, 1982
Drewinko B, Loo TL, Gottlieb JA: A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells. Cancer Res 36:511–515, 1976
Barranco SC, Townsend, Jr CM, Quraishi MA, Burger NL, Nevill HC, Howell KH, Boerwinkle WR: Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs. Invest N Drugs, 1:103–113, 1983
Tropé C, Aspergren K, Kullander S, Astedt B: Heterogeneous response of disseminated human ovarian cancers to cytostatistics in vitro. Acta Obstet Gynecol Scnad 58:543–546, 1979
Tropé C, Hakansson L, Dencker H: Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs. Neoplasma 22:423–430, 1975
Hakansson L, Tropé C: On the presence within tumours of clones that differ in sensitivity to cytostatic drugs. Acta Path Microbiol Scand Sec A 82:35–40, 1974
Heppner GH, Dexter DL, DeNucci T, Miller FR, Calabresi P: Heterogeneity in drug sensitivity among tumor cell sub-populations of a single mammary tumor. Cancer Res 38:3758–3763, 1978
Levin VA, Edwards MS: Chemotherapy of primary malignant gliomas. In Thomas DGT, Graham DI (eds): Brain Tumours. Butterworths, London, 1980, pp. 344–358
Geran RI, Congleton GF, Dudeck LE, Abbott BJ, Gargus JL: A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. Cancer Chemother Rep 4:53–87, 1974
Levin VA, Freeman-Dove MA, Maroten CE: Dianhydrogalactitol (NSC-132313) pharmaco-kinetics in normal and tumor bearing rat brain and antitumor activity against three intracerebral rodent tumors. J Natl Cancer Inst 56:535–539, 1976
Espana P, Wiernik PH, Walker MD: Phase II study of dianhydrogalactitol in malignant glioma. Cancer Chemother Rep 62:1199–1200, 1978
Egan RT, Childs DS, Layton DD, Laws, Jr ER, Bisel HF, Holbrook MA, Fleming TR: Dianhydrogalactitol and Radiation Therapy. JAMA 241:2046–2050, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rubin, N.H., Casartelli, C., Macik, B.G. et al. In vitro cellular characteristics and survival responses of human astrocytoma clones to chloroethyl-nitrosoureas and dianhydrogalactitol. Invest New Drugs 1, 129–137 (1983). https://doi.org/10.1007/BF00172071
Issue Date:
DOI: https://doi.org/10.1007/BF00172071